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Abstract 
 
Scope: Phytophenols present in cereals are metabolised to compounds that could be partly 
responsible for the reduced risk of chronic diseases and all-cause mortality associated with 
fibre-rich diets. The bioavailability, form and in vivo concentrations of these metabolites 
requires to be established.  
Materials/Methods: Eight healthy volunteers consumed a test meal containing a 
recommended dose (40 g) and high dose (120 g) of ready-to-eat wheat bran cereal and the 
systemic and colonic metabolites determined quantitatively by LC-MS.  
Conclusion: Analysis of the systemic metabolomes demonstrated that a wide range of 
phytophenols were absorbed/excreted (43 metabolites) within five hours of consumption. 
These included 16 of the 21 major parent compounds identified in the intervention product 
and several of these were also found to be significantly increased in the colon. Not all of the 
metabolites were increased with the higher dose, suggesting some limitation in absorption 
due to intrinsic factors and/or the food matrix. Many compounds identified (e.g. ferulic acid 
and major metabolites) exhibit anti-inflammatory activity and impact on redox pathways. The 
combination of postprandial absorption and delivery to the colon, as well as hepatic recycling 
of the metabolites at these concentrations is likely to be beneficial to both systemic and gut 
health. 
 
 
  
1. Introduction 
 
Diets containing whole-grain (WG) cereals can be protective against several cancers and 
metabolic disorders such as type 2 diabetes (T2DM), cardiovascular disease (CVD) and 
coronary artery disease (CAD). This is clearly demonstrated through both epidemiological 
evidence and intervention studies [1-8]. There are many factors, which may contribute to 
disease development, but subclinical inflammation is recognised as an important aspect [6]. 
WG cereals have been shown to impact on inflammatory markers, but there is a gap in the 
knowledge as to the bioactive dietary factors responsible [7,8]. The biological effects are 
mainly attributed to the fibre and the non-nutrient phytochemical content of WG cereals. 
Phytochemicals, and in particular phytophenols are of particular interest, as these are located 
in the outer layer of the grain and in the germ fraction; the bran fraction playing the more 
important role due to the germ being released during cereal processing [9,10]. The biological 
activity of the phytophenols depends on bioaccessibility from the food matrix, as well as 
bioavailability, metabolism and catabolism in vivo [11]. It is important that the biological 
effects should not just be attributed to the parent compounds present in foods, but also to the 
various metabolites produced in the body [12]. The small intestine plays a major role in 
absorption and metabolism of dietary phytophenols. However, many of these compounds, 
especially those attached to other cellular components such as fibre are not absorbed early in 
the gastrointestinal tract and are delivered to the colon relatively intact, where they are 
extensively metabolised by the gut microbiota prior to being absorbed and/or excreted [13]. 
Additionally, the microbial species can be influenced by dietary intake with consequences for 
impacting on human health [14]. When absorbed from the colon, microbial metabolites can 
be transported via the hepatic portal system, where they can generate numerous circulating 
metabolites [15]. In order to comment on potential health benefits of dietary constituents, it is 
important to determine the bioavailabilty and structure of these potentially bioactive 
metabolites [16]. The aim of this study is to identify and quantify the main phytophenol 
metabolites delivered to both the colon and to the systemic circulation after consumption of 
ready-to-eat wheat bran cereal and additionally to determine whether their absorption is 
concentration dependant.  
 
2. Materials and Methods 
 
2.1 Study Design 
 Volunteers recruited undertook a general health screen to check they meet the study criteria 
and complete food frequency and physical activity questionnaires. The volunteers recruited 
were asked to follow their normal diet until three days before the intervention at which time 
they consumed a low phytochemical diet and completed food diaries. Volunteers were fasted 
for twelve hours prior to commencing the intervention and were not permitted to drink or eat 
anything within the first five hours following consumption. For the remaining intervention 
period (24 hours), volunteers could consume the low phytochemical diet. Each volunteer 
consumed wheat bran-rich cereal at a recommended serving (40 g) along with semi-skimmed 
milk (125 mL) and the high-fibre serving (120 g) with semi-skimmed milk (375 mL).  These 
serving provided approximately 10.8 g and 32.4 g of wheat bran fibre respectively (data 
provided by the manufacturer). There was a washout period of at least two week between 
interventions. Baseline faecal, blood and urine sample were collected prior to beginning the 
intervention and blood and urine samples were collected at 1, 3 and 5 hours during the 
intervention period (Figure 1A) Additionally, urine was collected throughout the twenty four 
hour study period and a fasted blood sample at 24 hours (data not shown).  The first faecal 
sample after completion of the study was also collected. Containers, cool bags and ice packs, 
along with clear guidance as to storing the urine and faecal samples were provided. The 
studies followed all the principles of Declaration of Helsinki and good clinical practice, and 
all procedures involving human subjects were reviewed and approved by the Human Studies 
Management Committee of the Rowett Institute of Nutrition and Health, University of 
Aberdeen, UK and the Rowett Institute Ethics Panel. The study was carried out from 
February 2012 until June 2012. 
 
2.2 Volunteer Recruitment 
 
Eight healthy volunteers; seven females and one male; Age  38.62 ± 10.8 (23-54) years; BMI 
23.39 ± 2.63 (19.94-26.85) kg m
-2
 were recruited for the study. Local ethical committee 
approval was received and written informed consent was obtained from each subject. 
Selection took place following a general medical screening made by a qualified medical 
doctor and confirmation of adherence to inclusion/exclusion criteria. Inclusion Criteria: 
healthy, non-smokers, between 18-55 years old, BMI between 18 and 30 kg m
-2
. Exclusion 
Criteria: Taking any prescribed medicines, analgesics, antipyretic, anti-inflammatory 
compounds or nutritional supplements. Volunteers who had taken antibiotics or who had 
given a large blood donation in last three months prior to taking part in the study were also 
excluded. Volunteers were asked to complete the validated Scottish Collaborative Group 
Food Frequency questionnaire to assess habitual fibre intake. Volunteers were provided with 
information on which foods to avoid for the three days prior to and during the intervention 
were asked to complete a four-day food diary during this period to check for compliance.  All 
eight volunteers took part in the acute intervention to assess bioavailability (Figure 1). 
 
2.3 Intervention Product 
 
The intervention product used for the study was commercially available All Bran original 
cereal (Kellogg’s). The intervention product was analysed as described previously [17]. In 
brief; samples (approx. 0.1 g dry weight; n=3) were suspended in HCl (0.2 mol dm
-3
; 3 cm
3
) 
and the free phenolic acids extracted into ethyl acetate (EtOAc; 5 cm
3
). The layers were 
separated by centrifugation (5 min; 1800 x g; 4 ºC), the extraction repeated three times and 
the EtOAc extracts combined. To liberate both the acid- and alkali-labile esterified phenolic 
acids, the aqueous fraction was sequentially hydrolysed by both alkali (NaOH; 1 mol dm
-3
; 
room temperature) and acid (HCl; 6 mol dm
-3
; 95 °C), extracting into EtOAc as described 
above. All extracts were left to stand over sodium sulphate (anhydrous) for one hour, filtered 
and the combined organic layers evaporated to dryness under reduced pressure at temperature 
not exceeding 40 °C. The extracts were then re-dissolved in methanol (0.5 cm
3
) and prepared 
for LC-MS analysis as described below. 
 
2.4 General Reagents 
 
The methanol used was LC-MS grade from Fluka, hydrochloric acid was analytical grade 
from Fisher, sulphatase (S9626) and glucuronidase (G7017) from Sigma; 13C- benzoic acid 
(ISOTEC TJ2365, 277746-250 mg), 4,7,8- tri-MelQx  (TRC A630000 12AZC-165-1). 
 
2.5 Human Sample Processing 
 
Blood was collected directly into heparinised tubes at the 0, 1, 3, 5 and 24 hour time points. 
The samples were centrifuged (4 C, 1500 x g, 15 min) within 45 minutes to separate the 
plasma.  Urine samples were measured by weight and volume at time same points up to five 
hours and then the total 24-hour sample collected. The harvested plasma and the urine was 
aliquoted and stored at –80 C.  The faecal samples were weighed, mixed and immediately 
frozen at –80 C.  Faecal samples were thawed, mixed once again, weighed and the faecal 
waters (FW) separated using a high speed centrifuge  (50,000 x g; 2 hours; 10 
o
C). The FW 
(supernatant) was carefully removed, aliquotted into eppendorfs and immediately stored at -
80
o
C for LC-MS analyses. Surplus of all the human samples was retained for use in future 
related research under signed consent by volunteers before participating in the study. 
 
2.6 Human Samples Analysis 
 
2.6.1 Conjugated systemic metabolites 
Urine and plasma samples were thawed to 4 ºC and 150 µl was transferred to an eppendorf 
and sulphatase (H-1 Helix pomatia; 0.5 units in citrate phosphate buffer 0.3 mol dm
-3
; pH6; 
120 µl) and glucuronidase (HP-2 Helix pomatia 100390 units/ml; 30 µl) were added. Samples 
were incubated for 18 hours at 37 ºC. IS1 (60 µl), IS2 (60 µl) and acidified (0.4 mol dm
-3
 
HCl) methanol (180 µl) were added. Vortexed and centrifuged (12,500 x g; 5 mins; 4 ºC).  
 
2.6.2 Faecal metabolites 
Faecal water samples were thawed to 4 ºC and 80 µl transferred to an eppendorf. Internal IS1 
(80 µl), IS2 (80 µl) and methanol (160 µl) were added Vortexed and centrifuged (12,500 x g; 
5 mins; 4 ºC). 
 
2.7 LC-MS Analysis 
 
Liquid chromatography separation of the metabolites produced was performed on an Agilent 
1100 HPLC system (Agilent Technologies, Wokingham, UK) using a Zorbax Eclipse 5µm, 
150 mm x 4mm column (Agilent Technologies). Three different gradients (1-3) were used to 
separate the different categories of metabolites and the mobile phase solvents in each case 
were water containing 0.1% acetic acid and acetonitrile containing 0.1% acetic acid. In all 
cases the flow rate was 300 µL/min with an injection volume of 5 µL. The LC eluent was 
directed into, without splitting, an ABI 3200 triple quadrupole mass spectrometer (Applied 
Biosystems, Warrington, UK) fitted with a Turbo Ion Spray™ (TIS) source. For LC methods 
1 and 2, the mass spectrometer was run in negative ion mode with the following source 
settings: ion spray voltage -4500 V, source temperature 400 ºC, Gases 1 and 2 set at 15 and 
40 respectively and the Curtain Gas set to 10. For LC method 3, the mass spectrometer was 
run in positive ion mode with the following source settings; ion spray voltage 5500, source 
temperature 400 C , Gases 1 and 2 set at 14 and 40 respectively and the Curtain Gas set at 
10. All the metabolites were quantified using multiple reaction monitoring. Standard 
solutions (10 ng/µL) for all analytes were prepared and pumped directly via a syringe pump. 
The ion transitions for each of the analytes were determined based upon their molecular ion 
and a strong fragment ion. For several categories of compounds, it was inevitable that their 
molecular ion and fragment ion would be the same, but this was overcome by their differing 
elution times. Their voltage parameters; declustering potential, collision energy and cell 
entrance/exit potentials were optimised individually for each analyte.  
 
2.8  Statistical analysis  
 
All data is expressed as mean  standard deviation. Metabolic data sets were analysed by 
multivariate analysis PCA (SIMPCA-P+). The effect of treatment over time (plasma and 
urine metabolites) was assessed by two-sided post-hoc t-tests and the faecal metabolites by 
log-scale Anova with post-hoc least significant different tests for each of the interventions 
using the volunteers as their own controls. Genstat version 13 (VSN International) was used 
for these calculations and there were no indications of departures from equal variances. 
 
3. Results 
 
Principal component analysis (PCA) showed that the overall metabolite profiles in urine 
differed at 0, 1, 3, and 5 hours following consumption of high (Figure 2A) and low (Figure 
2B) amounts of wheat bran. The urinary metabolome within the first five hours of 
consumption of the intervention product gives the best indication of the metabolites that have 
been absorbed early in the gastrointestinal tract. As concentrations are generally higher in the 
urine compared to plasma, changes in metabolites present at lower amounts can be 
determined. The data showed some inter-individual variation, but despite this, quantitative 
analysis of the individual metabolites present in urine showed that around 43 metabolites 
were significantly modulated by the intervention. Of the 21 major parent metabolites 
identified to be present in wheat bran (Table 1), 16 were significantly increased in urine 
following consumption (Table 2). In general, most metabolites were excreted at higher 
concentrations during the acute intervention with a high dose of wheat bran. For some 
metabolites the increase was less than three-fold suggesting that the amount of metabolites 
absorbed early in the gastrointestinal tract may be limited by intrinsic factors, such as gut 
transporters, enzymes and food matrix effects [18]. Absorption is also likely to be influenced 
by other components in the plant matrix or in the milk. However, the ratio of cereal to milk 
was kept constant to standardise these effects. As observed previously the recovery of the 
hydroxylated benzoic acids in the urine was substantially higher than the recovery of 
hydroxycinnamic acids, suggesting that these compounds are more easily or competitively 
absorbed early in the gastrointestinal tract [19].  
 
The overall profiles of the metabolites in plasma for both the high and low wheat bran 
interventions (Figure 3A and 3B) were not as clearly discriminated when compared to the 
PCA of the urinary metabolites (Figure 2A and 2B). This is likely to reflect the lower 
concentration of metabolites present in plasma, as well as high variability due to dynamic 
exchange. However, the major metabolites found in wheatbran; ferulic acid and the ferulic 5-
5 dimer were significantly (p < 0.05) increased in the plasma, as were 2,6-dihydroxybenzoic 
acid, 3,5-dihydroxycinnamic acid, syringic acid and phenylacetic acid (Tables 5 and 6). It 
should be noted that certain metabolites, particularly; phenylacetic acid, 4-
hydroxyphenylacetic acid, phenylpyruvic acid, 4-hydroxyphenylpyruvic acid, phenyllactic 
acid, 4-hydroxyphenyllactic acid, indole-3-acetic acid, indole-3pyruvic acid, indole-3-lactic 
acid and p-cresol were present at high amounts. These were consistant throughout and not 
significantly affected by consumption of the intervention product. These have been shown 
previously to be gut metabolites of the aromatic amino acids and could be a consequence of 
the low phytochemical diet on which the volunteers were placed prior to the intervention 
[20]. 
 
PCA shows discrimination between the faecal metabolites produced prior to consuming the 
wheat bran (control) and at 24 hours after consuming both the high (120 g) and low (40 g) 
doses of wheat bran (Figure 4). The colonic metabolites have been analysed with each 
volunteer as their own control. This is necessary for work concerning the gut microbiota, as 
there is generally large inter-individual variation in the species present [21]. Of the 
metabolites quantitatively analysed, 16 were significantly modulated by the intervention. The 
metabolites significantly increased by consumption of the high dose of wheat bran were 
ferulic acid, the hydrogenated product of the 5-5 linked ferulic acid dimer, the 8-5 linked 
ferulic acid dimer and 2-hydroxyphenylpropionic acid. Enterolactone and 3,5-
dihydroxybenzoic acid were significantly increased on the intervention with the low dose of 
wheat bran only. Again, high amounts of metabolites likely to be derived from metabolism of 
protein were present in the faecal samples collected throughout the intervention. Some of 
these (p-cresol, phenylacetic acid, 4-hydroxyphenylacetic acid, phenyllactic acid, 4-
hydroxyphenyllactic acid, indole-3-acetic, indole-3pyruvic and indole-3-lactic acid) were 
found to be substantially lower in the colon 24 hours following consumption of the large dose 
of the wheat bran intervention product, although these decreases were not significant.  
 
 
4. Discussion 
 
Consumption of ready-to-eat wheat bran cereal resulted in significant absorption of 
phytophenols early in the gastrointestinal tract and urinary excretion within five hours of 
consuming the intervention product. Many of the phytophenols identified (vanillic acid, 4-
hydroxy-3-methoxyacetophenone, ferulic acid and sinapic acid) were previously shown to 
have anti-inflammatory activity [22], to inhibit peroxidase and lipoxygenase enzymes 
(salicylic acid, 4-hydroxybenzoic acid, protocatechuic acid, 2,5- and 3,5-dihydroxybenzoic 
acids) [23,24],  and to be redox active [25]. The metabolites that were found to be 
significantly increased in the colon (as measured by their presence in faecal samples) 24 
hours following the intervention were ferulic acid, the hydrogenated product of the 5-5 linked 
dimer and the 8-5 linked ferulic dimer. Wheat bran is a particularly rich in the 5-5-linked 
dimer of ferulic acid and the hydrogenated product of this dimer is the major form produced 
by the gut bacteria at physiological concentrations [26].
 
Monomeric and dimeric ferulic acid 
and the major gut metabolites of these compounds are potent anti-inflammatory compounds, 
at low concentrations, which easily achievable in vivo [22,26]. Bioavailability of certain 
classes of phytophenols have been extensively reviewed [27]. Several studies have reported 
the availablity of free ferulic acid early in the GI tract, but there are fewer studies reporting 
the availability of ferulic acid bound to other cell wall components such as arabinoxylans [28-
30]. Increased bioavailabilty of ferulic acid and its metabolites was observed following 
consumption of processed whole wheat bread, this was associated with significantly lower 
anti-inflammatory cytokines in LPS-stimulated blood following consumption [31]. There 
have been very few human studies reporting the bioavailability of the ferulic dimers, which 
are major components of wheat bran in either the gut or systemic circulation. Coffee-derived 
ferulic acid dimers were shown to be bioavailable in both plasma and urine [32]. Interestingly 
a trend toward lower plasma plasminogen activator inhibitor 1 with higher excretion of 
ferulic acid and dehydrodiferulic acid was also reported [33].  Of the many factors considered 
to contribute to the development of diseases such as CVD, CAD and T2DM, there is 
substantial evidence for the chronic low-grade stimulation of inflammatory mediators [34]. 
Diets rich in fibre, such as wheat bran have potential to deliver anti-inflammatory compounds 
directly to the gut and through hepatic circulation in a sustained manner to the vascular 
system, as well as delivering an acute postprandial dose. Indeed, whole-grain wheat 
consumption reduced inflammation in a randomised controlled trial on overweight and obese 
individuals, with concomitant increases in ferulic acid and metabolites [35]. Inflammatory 
status and lipid profiles were also improved by ferulic acid supplementation in 
hypercholesterolemic subjects [36]. In summary, this data demonstrates that several 
phytochemicals and their metabolites present in wheat bran were found to be significantly 
increased in urine, plasma and faecal water samples obtained from volunteers after 
consuming wheat bran based ready-to-eat cereal. Many of the metabolites, and in particular, 
ferulic acid and its derivatives are known to exhibit anti-inflammatory activity, impact on 
redox pathways [22-25], with potential to deliver additional neurological benefits [38,39]. 
This may, in part, explain the beneficial effects of wholegrain consumption on systemic, gut 
and general health. 
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Figure Legends 
 Figure 1:  Human intervention study design.  
 
Figure Principal component analysis plot (unweighted) for all metabolites measured in urine 
obtained from volunteers (n=8) at 0,1,3, and 5 hours after consuming a high (A; 120 g) and  
low (B; 40 g) dose of wheat bran.  
 
Figure 3: Principal component analysis plot (unweighted) for all metabolites measured in 
plasma obtained from volunteers (n=8) at 0,1,3, and 5 hours after consuming a high (A; 120 
g) and  low (B; 40 g) dose of wheat bran.  
 
Figure 4: Principal component analysis plot (unweighted) for all metabolites measured in 
faecal waters obtained from volunteers (n=8) before (control) and 24 hours after consuming 
high (Intervention A; 120 g) and low (Intervention B; 40 g) doses of wheat bran. 
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